Cell and Gene Therapy
🇺🇸 FDAFDA news and analysis for pharmaceutical BD, investment, and market access
Articles about Cell and Gene Therapy
Showing 1–12 of 14 articles
Quick answer
NovaPharmaNews Cell and Gene Therapy hub for FDA covers 14 published articles — news and analysis for pharma BD, investors, and market access teams. Browse related topics below or explore companies, pipeline, and events linked from each story.
Exclusive: FDA issues industry-friendly gene therapy guidance: What BD teams need to know
FDA Issues June 2026 Guidance: Gene Therapy, Payor Comms, and CMC Flexibilities
Best Biotech News Sources: How Legend Biotech Emerged as a Rare Market Winner
Legend Biotech surges on early in vivo CAR-T data for lymphoma
ASGCT Annual Meeting 2026: Live Event Coverage and Key Insights
FDA Issues Draft Guidance to Help Accelerate Cell and Gene Therapies for Patients
Fierce Biotech Week: Key Takeaways and Emerging Trends
ASGCT: Key Manufacturing Innovations Day 1
ASGCT 2024: Gene Therapy Advancements Day 1 Roundup
ASGCT: Manufacturing Innovations Take Center Stage
CAR-T Therapy Clinical Trials: Insights from ASCO 2026 and FDA Approval Implications
Clinical Outsourcing Group: Pharma News Roundup (April 28, 2026)
Frequently asked questions
How often is this topic updated?
New articles are published continuously as regulatory, clinical, and commercial signals break. Use the content-type filters for latest news vs in-depth analysis.
Where does this coverage come from?
Editorial intelligence combines FDA openFDA, ClinicalTrials.gov, SEC EDGAR, congress calendars, and analyst reporting. See our data sources policy for attribution.